Drugs / Alutard SQ
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT00135629 | Oct 2002 → Jan 2008 | seasonal allergic rhinitis | Imperial College London | Completed | No outcome recorded |
| Phase 3 | NCT00135642 | Feb 1996 → Oct 1998 | seasonal allergic rhinitis | Imperial College London | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04929093 | Jun 2020 → Apr 2021 | allergic rhinitis | Beijing Tongren Hospital | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00807547 Comparator | Apr → Oct 2008 | allergic disease | ALK-Abelló A/S | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alutard SQ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00135629 ↗ |
| Modality | Vaccine | “alum-adsorbed grass pollen vaccine” NCT00135629 ↗ |
| Route | Subcutaneous | “Subcutaneous Alutard SQ grass pollen (Phleum pratense)” NCT00135642 ↗ |